Table 1

Characteristics of Eligible Patient Population, Study vs. Control Sites
STUDY (n = 16,584) CONTROL (n = 13,423) P-Value
Mean Age (yrs) 61 60 <.0001
% Female 49.9 51.8 <.0001
Race/Ethnicity (%)
Asian/PI 9.0 12.3 <.0001
Black 6.1 16.2 <.0001
Hispanic 9.8 12.6 <.0001
Native American 1.3 1.3 0.97
White 62.0 44.4 <.0001
Other/Multiple 2.9 2.2 <.0001
Missing Race 8.9 11.0 <.0001
Comorbidities
Mean Number of Comorbidities* 1.23 1.25 0.01
Has Diabetes (%) 77.5 80.4 <.0001
Current Smoker (%) 8.9 9.0 0.77
Mean Risk Factor Values at Baseline**
Systolic Blood Pressure (mm Hg) 131 132 0.18
LDL-cholesterol (mg/dL) 100 98 <0.001
Hemoglobin A1c (%) 7.3 7.3 0.13
Mean # Medication Classes, Baseline
Blood Pressure Medications 1.74 1.82 <.0001
Diabetes Medications 1.22 1.23 0.19
Dyslipidemia Medications 0.70 0.70 0.35
On Max Med Therapy at Baseline (%)
Simvastatin/Atorvastatin 80 mg 12.3 13.8 <.0001
3 or more Blood Pressure Meds 27.8 31.0 <.0001
Insulin, if has diabetes 20.0 20.5 0.38
Baseline control rates (%) Entire PHASE Populations - by priority level
Priority 1: SBP <140 mmHg 83.5 81.8
Priority 4: SBP <130 mmHg 61.1 60.7
Priority 2: LDL-c <130 mg/dL 90.2 90.2
Priority 5: LDL-c <100 mg/dL 71.8 71.7
Priority 3: A1c <9% 90.3 90.9
Priority 6: A1c <7% 60.5 60.0

*Comorbidity count based on whether patient is flagged in the Population Management Tool as being in these populations: abdominal aortic aneurism, coronary artery disease, chronic kidney disease, diabetes, peripheral artery disease, and cerebrovascular disease.

Selby et al.

Selby et al. BMC Health Services Research 2012 12:183   doi:10.1186/1472-6963-12-183

Open Data